Hot Off the Presses: Roche is Hiring R&D Scientists???????
I was sitting around minding my own business (well sort of) and I received the following e-mail message. People must be reading BioJobBlog or something!
In the middle of the worst national job market since the early 1980's, Roche Pharma Research in Nutley, New Jersey is hiring. Specifically, this world class R&D center is seeking to hire 40 scientists to strengthen its research efforts to develop drugs to combat inflammatory diseases like arthritis and asthma.
In addition to Inflammation, Nutley continues to be the headquarters for Roche's Oncology Disease Biology Area, as well as RNA Therapeutics (an emerging area in understanding how genes are turned on and off in cells).
Focusing on drug discovery and non-clinical development, the site has a long tradition of discovering innovative new medicines.
Marcie Geremakis of Roche HR is available to discuss the efforts to recruit the new scientists and why Nutley is an outstanding environment for scientists. A number of scientists are available to discuss the following:
-
Roche's cutting edge scientific approaches to drug discovery focused on meeting the demands of the emerging need for personalized healthcare.
- Roche's intent to provide its scientists with the environment necessary to push forward novel ideas while challenging old paradigms.
- The ability to use state-of-the-art technology and collaborate with Roche's world class scientists across the globe engaged in biomarker discovery, novel biologics platforms, RNAi and diagnostics.
With well over 100 projects in research and more than 60 New Molecular Entities in development, Roche’s pipeline is among the best in the pharmaceuticals industry.
Please call me at 212-468-4306 or e-mail me at jillian.chertok@mslworldwide.com if you would like any additional information, or are interested in scheduling a time to speak with Marcie or one of the scientists at Roche.
I must disclose that I have no financial arrangement with this agency nor have I ever done business with them before. But, I figured if there are jobs to be had in this economy I ought to pass them on to folks who are looking.
Until next time...
Good Luck and Good Job Hunting!!!!!
According to a report yesterday,
The Belgian chemical manufacturer Solvay 
Word on the street suggests that Roche has severed its relationship with the Pharmaceutical Manufacturers of America (PhRMA) the trade group that represents and lobbies on behalf of the pharmaceutical industry. The recent purchase of Genentech must have convinced the venerable 100 year old pharmaceutical company that proteins not small molecule drugs are the key to its future.
The New York Times reported
Roche announced Tuesday that it will replace Arthur Levinson, PhD, Genentech’s current CEO and American biotechnology pioneer, with Pacal Soriot, DVM, MBA who currently leads Roche’s worldwide commercial operations. Dr. Levinson will become Chairman of Genentech’s newly configured board of directors but no longer have control over day-to-day operations at the company. Mr. Soriot will become CEO of Genentech and head all of Roche’s pharmaceutical activities in the US. Some of the other changes that will occur at the company include: Susan Desmond-Hellmann, Genentech’s president of product development, will move into an advisory role after the middle of this year. Genentech CFO David Ebersman is leaving the company and Ian Clark, who heads commercial operations for Genentech, will be chief marketing officer of Roche’s pharma division.
Since 2007, approximately 80,000 pharmaceutical jobs have been eliminated. The recent consolidation in the industry, e.g., Merck-Schering, Pfizer-Wyeth and Roche-Genentech suggests that many more life sciences jobs will be lost over the next year or so. Typically, to avoid law suits and possible discrimination claims, most companies will layoff a mixture of experienced and entry level employees that cover the racial, religious and age spectra. For those of you who may not know, Americans who are 40 and older constitute a “protected class of employees.” In other words, companies that layoff employees cannot disproportionately give pink slips to employees 40 years of age or older. This law was enacted because older employees typically have higher salaries and have accrued more benefits and vacation time than their more junior counterparts and eliminating them can drastically cut costs. While most companies are careful to layoff a mixture of junior and senior employees during large layoffs, a quick perusal of the demographics of employees who lose their jobs reveals that many of them are older, more experienced workers. Sacrificing a few entry level employees (to prevent any red flags) is worth it to the accountants who charged with cutting costs and orchestrating large corporate layoffs.
It’s official! Roche has secured more than 96 percent of shares in Genentech Inc, completing its $46.8 billion buyout of the U.S. biotech group. It now holds some 93 percent of outstanding Genentech shares, a further 3 percent are guaranteed to be delivered within the next three business days and it will integrate the U.S. biotech group as soon as possible.
The old baseball adage which says that “you can’t tell the players apart without a program” is particularly apt when it comes to tracing the M &A activity that led to the creation of some today's largest pharmaceutical companies.
Late last week, Roche raised the price of its hostile offer to buy out
While the domino theory was incorrect when it came to the spread of communism during the Cold War, there may be a kernel of truth to it when it is applied to today’s pharmaceutical industry. On Tuesday, Pfizer announced that it would lay off 800 researchers. Not to be outdone by Pfizer,
As expected,
On the heels of yesterday’s announcement that it wants to buy Genentech, Roche, in a surprise move,
At lunch the other day, I was telling a bunch of people about how brilliant Roche’s biotechnology strategy has been for the past 20 years or so. All of this changed for me on Monday,
Monoclonal antibodies (MAbs)
There are currently two injectable products on the market that are used to treat chronic Hepatitis C infections. Both products,
Swiss pharmaceuticals producer Roche Holding AG said Thursday


